Categories
Emcure Pharmaceuticals Limited — Board Meeting, 05-05-2026: Outcome of Board Meeting
05-05-2026 · 02:05 pm
Emcure Pharma: Q4 & FY26 consolidated results approved. FY26 revenue ₹9,204 Cr (+16.6%), PAT ₹941 Cr (+33.1%). Q4 revenue ₹2,470 Cr (+16.7%), PAT ₹244 Cr (+23.6%). ₹3.60/share final dividend declared. MD Satish Mehta & Dr. Mukund Gurjar re-appointed.
No comments yet. Be the first to comment!